News
JNJ
258.45
+1.44%
3.67
3 ‘Strong Buy’ Dividend Aristocrats on Analysts’ Watch List
TipRanks · 9h ago
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Seeking Alpha · 11h ago
Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock (JNJ)?
Simply Wall St · 14h ago
Pharma lobby group sues Trump administration over MFN pricing
Seeking Alpha · 14h ago
9 Of 11 Sectors Fall Wednesday As Defensives Lead
Benzinga · 15h ago
Johnson & Johnson Price Target Maintained With a $287.00/Share by Guggenheim
Dow Jones · 16h ago
Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target
Benzinga · 17h ago
Morgan Stanley Releases a Buy Rating on Johnson & Johnson (JNJ)
TipRanks · 17h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)
TipRanks · 18h ago
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
Barchart · 21h ago
Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO
Seeking Alpha · 1d ago
9 Of 11 Sectors Rise In Tuesday Trading As Defensives Lead
Benzinga · 1d ago
PFE vs. JNJ: Which Stock Is the Better Value Option?
NASDAQ · 1d ago
Johnson & Johnson Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
Johnson & Johnson (JNJ) ICOTYDE Update Keeps Fair Value In Focus
Simply Wall St · 1d ago
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290
Benzinga · 1d ago
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
NASDAQ · 1d ago
Johnson & Johnson price target raised to $290 from $287 at RBC Capital
TipRanks · 1d ago
RBC Capital Keeps Their Buy Rating on Johnson & Johnson (JNJ)
TipRanks · 1d ago
Johnson & Johnson: The Next Patent Cliff Will Test A Replacement Engine That It Is Already Working On
Seeking Alpha · 1d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform.